|
Post by Tony Crispino on Apr 10, 2014 16:56:32 GMT -8
From the cancer Network wire: Possible Biomarker for Enzalutamide in Prostate Cancer"...researchers have identified a potential biomarker that may confer inherent resistance to enzalutamide. The marker, a variant form of the androgen receptor called AR-V7, can be detected in circulating tumor cells (CTCs) that can be obtained with a blood draw from patients prior to the start of the therapy."
|
|
Jerry
Junior Member
Posts: 44
|
Post by Jerry on Apr 17, 2014 3:02:37 GMT -8
...or can be detected by tumor biopsy, which might be easier to catch vs. CTCs...and my experience is that insurance companies are not kind to the CTC test..$$$
There were only 31 patients, but very interesting.
|
|
|
Post by Eugene on Apr 17, 2014 17:28:17 GMT -8
I am a prostate cancer patient in the advanced stages. I received enzalutamide after having previously responded well to abiraterone. Enzalutamide did not work at all (PSA kept going up), but my doctor recommended that I stick with the drug for several months before declaring defeat. I wish I had been able to find out ahead of time that enzalutamide was not going to work in my body. If the AR-V7 test had been available, and it could be tested from my circulating cancer cells, I would have definitely wanted to have the test. I probably would have chosen a different treatment.
|
|